Aptar Digital Health today announced survey findings showcasing the impact of its iPump connected assistant for medication adherence. The SPEED survey looked at iPump’s effect on adherence to Stallergenes Greer’s sublingual liquid immunotherapy (SLIT). Stallergenes Greer will present findings at the CFA congress (Congrès Francophone d’Allergologie) in Paris this week. iPump, developed in conjunction with […]
aptarpharma
Nasal vaccine devices: Design and regulatory need-to-knows
Nasal vaccine devices have the potential to offer more convenient and more effective protection against a variety of viruses. In 2024, the FDA approved a nasal spray as the first at-home influenza vaccination, allowing adults to vaccinate themselves or someone in their care without a needle jab or a trip to the pharmacy. Intranasal vaccines […]
Aptar Pharma inks dev deal with Pulmotree for non-propellant liquid inhaler platform
Aptar Pharma announced that it entered into an exclusive collaboration agreement with Pulmotree to develop a liquid inhaler platform. The collaboration enables Aptar to lead the development and promotion of the Kolibri non-propellant liquid inhaler (NPLI) platform. Under the agreement, Aptar intends to provide Pulmotree with full support to accelerate growth. The company serves as […]
Aptar Group’s Unidose system to deliver neffy nasal epinephrine
Aptar announced today that its Unidose liquid system received FDA approval to deliver ARS Pharmaceuticals’ neffy (epinephrine nasal spray). ARS won FDA approval last week for neffy as an emergency treatment for patients with Type I allergic reactions, including anaphylaxis. It marked a major innovation in epinephrine delivery as the first and only needle-free treatment […]
Aptar wins FDA contract to study low global warning potential metered dose inhalers
Aptar Pharma announced today that it entered into a contract with the FDA to work on low global warming potential (low-GWP) inhalers. The FDA enlisted Aptar to study the challenges of developing low-GWP propellant metered dose inhalers (MDIs). The Crystal Lake, Illinois-based company expects its study to help define the potential target product profile of […]
Aptar Pharma launches metal-free nasal spray pump
Aptar Pharma announced today that it launched its first metal-free, multidose nasal spray pump, called the APF Futurity. Crystal Lake, Illinois-based Aptar developed APF Futurity to deliver nasal saline and other comparable over-the-counter (OTC) formulations. The company designed the pump specifically for recyclability. It represents Aptar’s first “highly recyclable” nasal spray pump, according to a […]
Aptar acquires Orbital dry powder inhaler license
Aptar Pharma announced today that it acquired the worldwide writes to Pharmaxis’ proprietary Orbital inhaler. Pharmaxis designed its Orbital technology to deliver high-payload dry powder to the lungs, helping to meet the need to deliver high doses of drugs such as antibiotics. According to a news release, the Orbital inhaler allows payloads of up to […]
FDA approves first nasally administered pharmaceutical treatment for dry eye
AptarGroup (NYSE:ATR) announced today that it received FDA approval for its nasal pump to deliver a pharmaceutical treatment for dry eye. Crystal Lake, Illinois–based Aptar said the patented Cartridge Pump System (CPS) is for the multidose delivery of preserved and non-preserved drug formulations. It has received approval as the device for delivering Oyster Point Pharma’s […]
Seelos, Aptar sign deal for Bidose system to deliver ketamine candidate
Seelos Therapeutics (NSDQ:SEEL) announced today that it partnered with AptarGroup (NYSE:ATR) for the Bidose liquid system device. The agreement includes the co-exclusive use and supply of Aptar Pharma’s Bidose device to deliver Seelos’ intranasal ketamine product candidate, SLS-002, for treating suicidality, depression and post-traumatic stress disorder (PTSD). Under the agreement, Seelos garners certain rights to […]
Aptar wins FDA clearance for ready-to-use seizure treatment device
AptarGroup today said it won FDA approval for its Unidose Liquid System that treats acute repetitive seizures in people who have epilepsy. The Unidose Liquid System is a device that delivers a nasal rescue treatment that is ready-to-use when and where a seizure cluster occurs. “This approval and successful market launch further demonstrate the broad […]
